microns are present and are more triglycerides-rich than very low-density lipoprotein particles. Finally, concerns have been raised recently about the inaccuracy of Friedewald LDL-C (underestimating the true LDL-C) when LDL-C is low, in particular if triglycerides are concomitantly moderately elevated or higher (>200 mg/dL). [5] [6] [7] Extremely low LDL-C (eg, ≤10 mg/dL) is more common now in the era of potent LDL lowering for high-risk patients, for whom guidelines recommend targeting LDL-C <70 mg/dL or even lower with therapies such as highintensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors. High-risk patients may be potentially undertreated if Friedewald LDL-C is used.
The question for clinicians who rely on LDL-C for management decisions then becomes, can we still accurately calculate LDL-C in light of all these factors, and if not, is there a better estimator than the Friedewald equation?
In this context, Sathiyakumar and colleagues 8 in this issue of Circulation examined the accuracy of Friedewald LDL-C compared with a novel method they had previously derived. 9 In 2013, Martin and colleagues 9 published their first report of a novel LDL-C calculation method (LDL-C N ) that substituted a sophisticated derivation of the variable triglycerides to VLDL-C ratio into the Friedewald original formula. Using a large subset derived from close to 1.3 million lipid profiles from a single database (Very Large Database of Lipids), they were able to create a 2×2 Sathiyakumar and coauthors now use this novel, more personalized method and the previously derived triglycerides:VLDL-C table, with the additional advantage of assessing the accuracy of their formula compared with the Friedewald equation depending on the fasting status of participants. Using the second wave of data from the same database, they included an even larger number of patient samples (≈1.5 million), about one third of which were nonfasting (defined as <10 hours since the last meal). However, unlike their original ratio derivation study, those patients with triglycerides ≥400 mg/dL were excluded from this analysis to provide a more direct comparison with the Friedewald formula. In addition, the actual time since last meal and information on race, obesity, and insulin resistance were not available.
These results corroborate findings from their previous study; the novel method was found to be consistently more accurate than the Friedewald formula across previously described clinical cut points for target LDL-C. This superiority was upheld in both fasting and nonfasting samples. In those with LDL-C <70 mg/dL, LDL-C N provided closer approximation to direct LDL-C by the vertical autoprofile ultracentrifugation method than the Friedewald equation and indeed, on the basis of their findings, was minimally affected by fasting status compared with the Friedewald equation. As triglycerides levels increased, the accuracy of both methods decreased for patients with low LDL-C, but LDL-C N still was superior. The overall message therefore is that the Friedewald equation is not as reliable in patients, especially among those with low LDL-C and at least moderately high triglycerides.
It should be noted, however, that the median ratio of triglycerides to VLDL-C in the fasting and nonfasting groups was 4.9 and 5.3, respectively, so the absolute difference in the numbers derived for LDL-C would be small compared with using the fixed ratio of 5 for patients who fall into less extreme ranges of triglycerides and LDL-C. This is part of the reason that the Friedewald equation has been applicable for most patients. However, as we continue to evolve into the field of precision medicine, this study highlights specific patients who would benefit from the novel method that greatly improves the accuracy of LDL-C calculation without added expense.
The main strength of this study lies in the novel, more personalized calculation of the ratio of triglycerides to VLDL-C and the immense and national sample size, with >500 000 patients in the nonfasting group. It should be noted that whether the patients actually had fasted for at least 10 hours before giving blood samples could not be verified, and it is known that in the community, strict fasts are not maintained by some. In this instance, however, the volume of data should be sufficient to account for any small degree of misclassification. Another potential limitation in accurate LDL-C determination by the LDL-C N would be the fact that the ratios of triglycerides to VLDL-C were not originally adjusted for other factors such as race, obesity, and insulin resistance that may affect triglycerides and VLDL-C levels and hence the ratio. In addition, the study excluded patients with triglycerides ≥400 mg/dL. These are higher-risk individuals for whom we would expect decreased accuracy of both the Friedewald equation and the novel method, and it would be interesting to see how the novel method compares with direct LDL-C measurement in these patients. These 2 issues open up areas for continued investigation.
In the United States, the emphasis of recent guidelines has shifted away from absolute LDL-C cut points to focus on percent and risk reduction with tools that do not require absolute LDL-C. 10 Nonetheless, a baseline lipid profile is often the first screening test obtained by providers, and accurate LDL-C levels are still of value to both providers and, perhaps more important, to patient education and to optimal treatment of high-risk patients. This study highlights important limitations with the Friedewald calculation, especially in nonfasting patients and those with low LDL-C and higher triglycerides. For those patients, for whom knowledge of absolute LDL-C would be desired, the novel method offers a superior calculation method, with no additional cost to patients or the healthcare system. Indeed, a national laboratory was proactive and has already adopted this innovative method for patient care, including for nonfasting lipid testing.
